Tissue inhibitor of metalloproteinases (TIMP)

Tissue inhibitors of metalloproteinases (TIMPs) are a family of four endogenous proteins (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) that serve as the primary regulators of matrix metalloproteinases (MMPs), a group of enzymes responsible for degrading the extracellular matrix (ECM) (Brew & Nagase, 2010, doi:10.1016/j.bbagen.2010.07.003). By binding to the active site of MMPs in a 1:1 stoichiometry, TIMPs maintain the structural integrity of tissues and regulate the remodeling processes essential for wound healing and development (Visse & Nagase, 2003, doi:10.1161/01.RES.0000068382.76863.E6). Beyond their inhibitory role, TIMPs are involved in complex signaling pathways that influence cell proliferation, apoptosis, and angiogenesis, often through interactions with cell surface receptors like CD63 or integrins (Stetler-Stevenson, 2008, doi:10.1126/scisignal.111re6). Dysregulation of the MMP/TIMP balance is a key driver in various pathologies, including cancer invasion and metastasis, rheumatoid arthritis, and fibrotic diseases of the heart, liver, and kidneys (Arpino et al., 2015, doi:10.1002/path.4556). While small-molecule MMP inhibitors were designed to mimic TIMP function, their clinical success has been limited by off-target effects; consequently, current research explores recombinant TIMPs and gene therapy to restore homeostatic control in diseased tissues (Moore & Crocker, 2012, doi:10.1007/s00441-011-1246-z).

Other names

TIMPsTissue inhibitors of matrix metalloproteinasesMetalloproteinase inhibitorsEndogenous MMP inhibitors

TIMPs inhibit matrix metalloproteinases (MMPs) by binding to their active site in a 1:1 molar ratio, using their N-terminal domain to coordinate with the catalytic zinc ion and block substrate access (Brew & Nagase, 2010, doi:10.1016/j.bbagen.2010.07.003).